– USA, CT – Quantum-Si Incorporated (Nasdaq: QSI), The Protein Sequencing Company, today announced the election of Scott Mendel to its Board of Directors.
About Scott Mendel
Scott Mendel has more than 30 years of financial and operational leadership experience in the life sciences, diagnostics, and healthcare industries. Currently, he serves as a board member for Visby Medical, Inc. and Akoya Biosciences, Inc. During his tenure at GenMark, Mr. Mendel also served as COO and CFO, overseeing the Company’s growth to $200 million in annual sales, which led to its purchase by Roche Diagnostics in 2021 for $1.8 billion. Previously, Mr. Mendel was CFO at The Active Network and GE HealthCare.
“By harnessing the power of its breakthrough technology and innovation, Quantum-Si is poised to take remarkable leaps forward, opening up new avenues for drug discovery and diagnostics,” said Mr. Mendel. “I look forward to contributing my experience to support Quantum-Si’s expansion as a leading player in the proteomics landscape.”
Mr. Mendel received a Master of Business Administration from the Kellogg School of Management at Northwestern University in Illinois and a Bachelor of Science in finance from Indiana University Bloomington.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.
For more information: https://www.quantum-si.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.